Floatz logo

Cytosin-Arabinosid

Refractory Anemia With Excess Blasts

University of Southern CaliforniaPhase 3Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
95/ 100

Competitive context

32 Active assets in the Refractory Anemia With Excess Blasts cohort.

Asset / SponsorPhaseRating
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BB
TACROLIMUS
Fred Hutchinson Cancer Center
Phase 2BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 3BB
Idarubicine
Fred Hutchinson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Cytosin-Arabinosid is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →